# Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography

> **NCT06022068** · PHASE1,PHASE2 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 14 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT06022068
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-01
- **Primary completion:** 2024-12-11
- **Final completion:** 2025-01-17
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022068, "Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06022068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*